231 related articles for article (PubMed ID: 27696457)
21. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.
Zhong H; Chiles K; Feldser D; Laughner E; Hanrahan C; Georgescu MM; Simons JW; Semenza GL
Cancer Res; 2000 Mar; 60(6):1541-5. PubMed ID: 10749120
[TBL] [Abstract][Full Text] [Related]
22. Prostate cancer heterogeneity: Discovering novel molecular targets for therapy.
Ciccarese C; Massari F; Iacovelli R; Fiorentino M; Montironi R; Di Nunno V; Giunchi F; Brunelli M; Tortora G
Cancer Treat Rev; 2017 Mar; 54():68-73. PubMed ID: 28231559
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
[TBL] [Abstract][Full Text] [Related]
24. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
25. HER2 Mediates PSMA/mGluR1-Driven Resistance to the DS-7423 Dual PI3K/mTOR Inhibitor in PTEN Wild-type Prostate Cancer Models.
Gómez V; Galazi M; Weitsman G; Monypenny J; Al-Salemee F; Barber PR; Ng K; Beatson R; Szokol B; Orfi L; Mullen G; Vanhaesebroeck B; Chowdhury S; Leung HY; Ng T
Mol Cancer Ther; 2022 Apr; 21(4):667-676. PubMed ID: 35086953
[TBL] [Abstract][Full Text] [Related]
26. PSMA redirects cell survival signaling from the MAPK to the PI3K-AKT pathways to promote the progression of prostate cancer.
Caromile LA; Dortche K; Rahman MM; Grant CL; Stoddard C; Ferrer FA; Shapiro LH
Sci Signal; 2017 Mar; 10(470):. PubMed ID: 28292957
[TBL] [Abstract][Full Text] [Related]
27. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
28. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
[TBL] [Abstract][Full Text] [Related]
29. MIIP inhibits the growth of prostate cancer via interaction with PP1α and negative modulation of AKT signaling.
Yan G; Ru Y; Yan F; Xiong X; Hu W; Pan T; Sun J; Zhang C; Wang Q; Li X
Cell Commun Signal; 2019 May; 17(1):44. PubMed ID: 31092266
[TBL] [Abstract][Full Text] [Related]
30. PI3K/AKT Pathway and Its Mediators in Thyroid Carcinomas.
Nozhat Z; Hedayati M
Mol Diagn Ther; 2016 Feb; 20(1):13-26. PubMed ID: 26597586
[TBL] [Abstract][Full Text] [Related]
31. Glyoxalase system in yeasts: structure, function, and physiology.
Inoue Y; Maeta K; Nomura W
Semin Cell Dev Biol; 2011 May; 22(3):278-84. PubMed ID: 21310260
[TBL] [Abstract][Full Text] [Related]
32. PKM2 Knockdown Induces Autophagic Cell Death via AKT/mTOR Pathway in Human Prostate Cancer Cells.
Dey P; Kundu A; Sachan R; Park JH; Ahn MY; Yoon K; Lee J; Kim ND; Kim IS; Lee BM; Kim HS
Cell Physiol Biochem; 2019; 52(6):1535-1552. PubMed ID: 31135122
[TBL] [Abstract][Full Text] [Related]
33. Leptin promotes epithelial-mesenchymal transition of breast cancer via the upregulation of pyruvate kinase M2.
Wei L; Li K; Pang X; Guo B; Su M; Huang Y; Wang N; Ji F; Zhong C; Yang J; Zhang Z; Jiang Y; Liu Y; Chen T
J Exp Clin Cancer Res; 2016 Oct; 35(1):166. PubMed ID: 27769315
[TBL] [Abstract][Full Text] [Related]
34. NVP-BEZ235, a dual PI3K/mTOR inhibitor, induces cell death through alternate routes in prostate cancer cells depending on the PTEN genotype.
Hong SW; Shin JS; Moon JH; Kim YS; Lee J; Choi EK; Ha SH; Lee DH; Chung HN; Kim JE; Kim KP; Hong YS; Lee JL; Lee WJ; Choi EK; Lee JS; Jin DH; Kim TW
Apoptosis; 2014 May; 19(5):895-904. PubMed ID: 24652480
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA-106b promotes pituitary tumor cell proliferation and invasion through PI3K/AKT signaling pathway by targeting PTEN.
Zhou K; Zhang T; Fan Y; Serick ; Du G; Wu P; Geng D
Tumour Biol; 2016 Oct; 37(10):13469-13477. PubMed ID: 27465551
[TBL] [Abstract][Full Text] [Related]
36. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.
Festuccia C; Angelucci A; Gravina GL; Biordi L; Millimaggi D; Muzi P; Vicentini C; Bologna M
Thromb Haemost; 2005 May; 93(5):964-75. PubMed ID: 15886816
[TBL] [Abstract][Full Text] [Related]
37. MiR-129 inhibits cell proliferation and metastasis by targeting ETS1 via PI3K/AKT/mTOR pathway in prostate cancer.
Xu S; Ge J; Zhang Z; Zhou W
Biomed Pharmacother; 2017 Dec; 96():634-641. PubMed ID: 29035829
[TBL] [Abstract][Full Text] [Related]
38. Analysis of complex protein kinase B signalling pathways in human prostate cancer samples.
Jendrossek V; Henkel M; Hennenlotter J; Vogel U; Ganswindt U; Müller I; Handrick R; Anastasiadis AG; Kuczyk M; Stenzl A; Belka C
BJU Int; 2008 Aug; 102(3):371-82. PubMed ID: 18476967
[TBL] [Abstract][Full Text] [Related]
39. Activation of PI3K/Akt/mTOR signaling pathway triggered by PTEN downregulation in the pathogenesis of Crohn's disease.
Long SH; He Y; Chen MH; Cao K; Chen YJ; Chen BL; Mao R; Zhang SH; Zhu ZH; Zeng ZR; Hu PJ
J Dig Dis; 2013 Dec; 14(12):662-9. PubMed ID: 23962154
[TBL] [Abstract][Full Text] [Related]
40. GPCR48/LGR4 promotes tumorigenesis of prostate cancer via PI3K/Akt signaling pathway.
Liang F; Yue J; Wang J; Zhang L; Fan R; Zhang H; Zhang Q
Med Oncol; 2015 Mar; 32(3):49. PubMed ID: 25636507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
